BAM
MRTX

Belpointe Asset Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Belpointe Asset Management’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-208
Closed -$7.73K – 3616
2023
Q1 		$7.73K Hold
208
– – ﹤0.01% 2846
2022
Q4 		$9.42K Buy
+208
New +$13.5K ﹤0.01% 2647

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Belpointe Asset Management's MRTX Position: Q2 2023 in Review

Belpointe Asset Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q2 2023, closing a stake of 208 shares — an estimated $7.73K sold.

Belpointe Asset Management first reported a position in MRTX in Q4 2022 and held it in 2 quarters. The position peaked at $9.42K in Q4 2022. 207 funds tracked by Wall St. Rank hold MRTX as of Q2 2023.

  • Belpointe Asset Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Belpointe Asset Management sold 208 Mirati Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $7.73K.
  • Belpointe Asset Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2022 and held it in 2 quarters.
  • Belpointe Asset Management's Mirati Therapeutics, Inc. Common Stock position peaked at $9.42K in Q4 2022.
  • 207 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Belpointe Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.